Egetis Therapeutics (EGTX) Fireside chat summary

Introduction and agenda

• The session featured a discussion with the CEO of a biotech company focused on rare disease development and commercialization in the U.S. and Europe.

Background and experience of the speaker

• The CEO has seven years at the helm, following nearly 20 years at AstraZeneca in roles spanning development, supply chain, finance, and international leadership.

• Returned to Sweden in 2015 to focus on late-stage R&D before joining the current company.

Current industry trends

• Rare diseases remain underdiagnosed, with increased awareness and diagnosis rates improving over recent years.

• Pricing and reimbursement processes in Europe are complex and lengthy, while U.S. market access is faster and more lucrative.

• U.S. specialist investors are increasingly interested in rare disease opportunities.